Micromet Buys Out MedImmune's Remaining Rights to Blinatumomab

BETHESDA, Md., Nov. 5, 2009 (GLOBE NEWSWIRE) -- Micromet, Inc. (Nasdaq:MITI), a
biopharmaceutical company developing novel, proprietary antibodies for the
treatment of cancer, inflammation and autoimmune diseases, today announced that
it has signed an agreement with MedImmune, LLC to buy out MedImmune's rights to
blinatumomab in North America, and to terminate the collaboration agreement
signed in 2003 under which MedImmune had been granted the right to develop and
commercialize blinatumomab in North America. As a result of this transaction,
Micromet now controls global rights to develop and commercialize blinatumomab.

In March 2009, MedImmune returned the North American rights to develop and
commercialize blinatumumab to Micromet, but retained an option to reacquire the
right to commercialize blinatumomab in North America. Under the terms of the
termination agreement, Micromet has now regained MedImmune's remaining rights
relating to blinatumomab as well as any other BiTE antibodies binding to
antigens relevant for hematological cancers that had been reserved for MedImmune
under the terminated agreement. Micromet will make upfront, milestone, and
royalty payments to MedImmune related to the development and North American net
sales of blinatumomab.

"The advancement of blinatumomab in the clinic is the top priority for
Micromet," said Micromet CEO Christian Itin. "With complete control over global
development and commercialization of blinatumomab, Micromet can develop an
integrated clinical and regulatory strategy across multiple commercial
territories, starting with the first pivotal study that we expect to initiate in
2010."

Blinatumomab is a novel therapeutic antibody that activates a patient's T cells
to seek out and destroy lymphoma and leukemia cells. At the recent meeting of
the European Hematological Association (EHA), Micromet announced that
blinatumomab had achieved its primary endpoint in an ongoing phase 2 clinical
trial in ALL patients. Micromet intends to initiate a pivotal trial of
blinatumomab in ALL patients next year.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary
antibodies for the treatment of cancer, inflammation and autoimmune diseases.
Its product development pipeline includes novel antibodies generated with its
proprietary BiTE(R) antibody platform, as well as conventional monoclonal
antibodies. Two of Micromet's BiTE antibodies and three of its conventional
antibodies are currently in clinical trials. Micromet's preclinical product
pipeline includes several novel BiTE antibodies generated with its proprietary
BiTE antibody platform technology. Micromet's collaboration partners include
sanofi-aventis, Bayer Schering Pharma, Nycomed, Merck Serono, and MedImmune.

The Micromet, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=6805

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and
uncertainties that could cause actual results to be materially different from
historical results or from any future results expressed or implied by such
forward-looking statements. These forward-looking statements include statements
regarding the development and commercialization of blinatumomab, including the
conduct and timing of future clinical trials involving this product candidate.
You are urged to consider statements that include the words "ongoing," "may,"
"will," "believes," "potential," "expects," "plans," "anticipates," "intends,"
or the negative of those words or other similar words to be uncertain and
forward-looking. Factors that may cause actual results to differ materially from
any future results expressed or implied by any forward-looking statements
include the risk that blinatumomab does not demonstrate safety and/or efficacy
in future clinical trials, the risk that we will not obtain approval to market
blinatumomab and the risks associated with reliance on outside financing to meet
capital requirements. These factors and others are more fully discussed in
Micromet's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30,
2009, filed with the SEC on August 6, 2009, as well as other filings by the
company with the SEC.

-0-
CONTACT: Micromet, Inc.
U.S. Media:
Andrea tenBroek
Chris Stamm
(781)-684-0770
micromet@schwartz-pr.com
U.S. Investors:
Susan Noonan
(212) 966-3650
susan@sanoonan.com
European Media:
Ludger Wess
+49 (40) 8816 5964
ludger@akampion.com
European Investors:
Ines-Regina Buth
+49 (30) 2363 2768
ines@akampion.com